Bruker Corp highlights advanced scientific instruments as investors watch the stock
Bruker Corp (BRKR) is a global provider of advanced scientific instruments and analytical solutions, with its stock performance linked to demand from academic, industrial, and healthcare research. The company's growth is driven by technological innovation, upgrades to its installed base, and geographic expansion in markets like materials science, life science, and pharmaceutical development. Bruker's instruments are crucial for precision measurements in various scientific fields, making its business sensitive to long-term funding and capital investment in research.
Guggenheim Maintains Bruker Corp(BRKR.US) With Buy Rating, Raises Target Price to $70
Guggenheim has reiterated its Buy rating on Bruker Corp (BRKR.US) and increased its price target to $70. This update suggests a continued positive outlook from the firm regarding the company's stock performance.
Guggenheim Maintains Bruker Corp(BRKR.US) With Buy Rating, Raises Target Price to $70
Guggenheim has reiterated its Buy rating for Bruker Corp (BRKR.US) and increased the target price to $70. This revision indicates an optimistic outlook from the firm regarding Bruker's future stock performance.
JPMorgan Maintains an “Overweight rating” on Bruker Corporation (BRKR)
JPMorgan analyst Casey Woodring raised the price target for Bruker Corporation (BRKR) to $65 from $45, maintaining an "Overweight rating" on the stock. This revised outlook follows Bruker's announcement of advancements in its microbiology and infection diagnostics portfolio at ASM Microbe 2026. The company detailed improvements to its MALDI Biotyper CA System and introduced new research-use tools, strengthening its position in clinical labs and outbreak investigation.
JPMorgan Maintains an “Overweight rating” on Bruker Corporation (BRKR)
JPMorgan analyst Casey Woodring raised the price target on Bruker Corporation (BRKR) to $65 from $45, maintaining an "Overweight rating" on the stock. Bruker also recently showcased advancements in its microbiology and infection diagnostics portfolio at ASM Microbe 2026, including FDA-approved updates to its MALDI Biotyper CA System and new research-use tools. The company produces diagnostic tests and scientific instruments, and the report also suggests considering AI stocks with potentially greater upside despite BRKR's investment potential.
Bruker Corp updates its scientific tools portfolio, shares tracked on NASDAQ
Bruker Corp (BRKR) is a significant player in scientific instruments and life-science tools, with its shares tracked on NASDAQ. The company draws analyst attention for its role in advanced proteomics and biopharma workflows, and its revenue is largely driven by mass spectrometry and NMR systems. Analysts focus on its earnings growth, operating margin, cash generation, and capital allocation, comparing it to peers like Thermo Fisher and Waters within the life-science tools sector.
Bruker Is Maintained at Overweight by Barclays
Barclays has maintained its Overweight rating on Bruker (NASDAQ: BRKR) stock. This indicates the firm's continued positive outlook on the company's performance. The article confirms Barclays' stance on Bruker.
Barclays Maintains Bruker Corp(BRKR.US) With Buy Rating, Raises Target Price to $60
Barclays has reiterated its Buy rating on Bruker Corp (BRKR.US) and increased its target price for the stock to $60. This reflects the firm's continued confidence in Bruker's financial prospects and market position.
Bruker Corp (BRKR) Institutional Confidence
Bruker Corp (BRKR) has an institutional shareholding score of 10.00, placing it first in the Healthcare Equipment & Supplies industry. This score reflects a 91.74% institutional shareholding proportion, which saw a 2.53% quarter-over-quarter decrease. Steven Cohen is the largest institutional shareholder, holding 707.94K shares.
Bruker Corp (BRKR) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Bruker Corp (BRKR), including its price momentum, support and resistance levels, and various technical indicators and moving averages. The current price momentum score is 7.38, suggesting suitability for range-bound swing trading between $45.19 and $64.78. Technical indicators show mixed signals, with some suggesting neutrality or oversold conditions, while moving averages predominantly indicate a buy signal.
Bruker Corp (BRKR) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for Bruker Corp (BRKR), including its current earnings forecast score, average analyst price target, and a breakdown of analyst ratings. It also addresses frequently asked questions about expected revenue, price targets, and past EPS performance. The data indicates a "Buy" trend based on analyst consensus, with an anticipated next-quarter EPS of $0.39 and revenue of $853.39M.
Bruker Corp (BRKR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a detailed revenue breakdown for Bruker Corp (BRKR), categorizing its income by business segments and geographical regions. It reveals that the "Product" segment accounts for the majority of revenue at 80.50%, with "Service and other revenue" making up the remainder. Geographically, Europe and the United States are the largest contributors to the company's revenue.
Bruker (BRKR) EVP exercises options, sells 2,000 pre-planned shares
Bruker Corp's EVP Mark Munch exercised stock options to acquire 2,000 shares at $22.19 per share and simultaneously sold all 2,000 shares in an open-market transaction at $54.76 per share. This transaction was pre-planned under a Rule 10b5-1 trading plan. Following these actions, Munch directly holds 128,443 shares of Bruker Common Stock.
Bruker Corp (BRKR) Stock Up 4.4% and Still Undervalued -- GF Sco
Bruker Corp (BRKR) saw its shares rise 4.4% to $56.63, trading below its GF Value™ of $62.56, which suggests the stock is undervalued. With a GF Score™ of 85/100, the company shows strong overall performance, particularly in valuation and profitability. However, insider selling of $0.2 million in the last three months indicates a need for caution.
Bruker Corp (BRKR) Stock Up 4.4% and Still Undervalued -- GF Score: 85/100
Bruker Corp (BRKR) stock rose 4.4% to $56.63, reflecting a 48.7% increase over the past year. Despite recent insider selling, the company is considered undervalued according to its GF Value™ of $62.56 and boasts a strong GF Score™ of 85/100, indicating potential for future returns. Its current forward P/E ratio of 26.7x is also significantly lower than its 5-year median, further suggesting undervaluation.
Broker Technologies (BRKR) files Form 144 to sell 2,000 shares (06/15/2026)
Broker Technologies, Inc. (BRKR) has filed a Form 144 intending to sell 2,000 shares of Common Stock on June 15, 2026, stemming from a stock option exercise to the issuer for cash. The filing also notes prior sales by Mark R. Munch in April and May 2026, each for 2,000 shares. Morgan Stanley Smith Barney LLC is listed as the broker handling the proposed transaction.
Bruker Corporation (NASDAQ: BRKR) files S-3 shelf for equity, debt and resale offerings
Bruker Corporation has filed an S-3 shelf registration statement to allow for future offerings and resales of an unlimited aggregate amount of various securities, including common stock, preferred stock, and debt securities. This registration provides Bruker with flexibility for future financing, and specific terms for any offering will be detailed in prospectus supplements. The filing also describes previously issued 6.375% Mandatory Convertible Preferred Stock, Series A, with a liquidation preference of $250 per share.
J.P. Morgan Maintains Bruker Corp(BRKR.US) With Buy Rating, Raises Target Price to $65
J.P. Morgan has reiterated its Buy rating on Bruker Corp (BRKR.US) and increased its target price for the stock to $65. This indicates a positive outlook from the investment bank regarding Bruker's future performance.
Is Bruker Corporation (BRKR) A Good Stock To Buy Now?
Bruker Corporation is positioned as a key beneficiary of the semiconductor industry’s shift towards advanced packaging and high-bandwidth memory (HBM), driving demand for its inspection and metrology tools. Despite its larger life sciences business being subdued, Bruker's semiconductor segment is experiencing significant growth, presenting a mispricing opportunity for investors. The company's tools are crucial for various stages of chip manufacturing, making it an embedded supplier to major semiconductor players.
DC-BRUKER-CORP
The article "DC-BRUKER-CORP" from Business Wire announces the MALDI Biotyper® sirius CA System. This system is designed to provide high-throughput microbial identification. Its purpose is to support efficient clinical laboratory workflows and improve diagnostic turnaround times.
Bruker Showcases Expanding Microbiology & Infection Diagnostics Portfolio at ASM Microbe 2026
Bruker Corporation's Microbiology & Infection Diagnostics division is presenting its expanded portfolio at ASM Microbe 2026. This includes enhancements to its MALDI Biotyper® sirius CA System for microbial identification, new solutions for rapid antimicrobial susceptibility testing in sepsis diagnostics, and additional offerings for its MALDI Biotyper® RUO/GP systems. Bruker is also introducing new software for next-generation sequencing workflows to enhance overall diagnostic capabilities.
BofA Securities Maintains Bruker Corp(BRKR.US) With Buy Rating, Announces Target Price $65
BofA Securities has reiterated its Buy rating on Bruker Corp (BRKR.US) and set a price target of $65. This indicates the firm's continued positive outlook on the company's stock performance.
Wolfe Research Initiates Bruker Corp(BRKR.US) With Hold Rating
Wolfe Research has initiated coverage on Bruker Corp (BRKR.US) with a "Hold" rating. The article title concisely conveys this financial news.
Bruker Corp. Hits Day High with 8.27% Surge in Strong Intraday Performance
Bruker Corp. (BRKR) saw its stock surge by 8.27% on May 29, 2026, reaching an intraday high of USD 58.98. The company has shown significant gains across various timeframes, including a 71.74% rise in the past month, outperforming the S&P 500. With a market capitalization of USD 5,745 million, Bruker Corp. demonstrates high management efficiency, a low debt-to-EBITDA ratio, 100% institutional ownership, and a 13.18% dividend yield.
Bruker Corporation Releases timsMRMS Platform for Analysis of Complex Chemical Mixtures
Bruker Corporation has launched its new timsMRMS mass spectrometry platform, designed for the analysis of ultra-complex chemical mixtures in the energy sector. This system combines trapped ion mobility spectrometry (tims) with magnetic resonance mass spectrometry (MRMS) to offer high-resolution data for applications like petroleum characterization and environmental analysis. The platform's ability to separate isomeric compounds and identify individual molecular components makes it a powerful tool for energy industry researchers.
Bruker’s new tool targets longer-lasting lithium batteries, cleaner fuels
Bruker Corporation has launched its new timsMRMS system, which combines Trapped Ion Mobility Spectrometry with Magnetic Resonance Mass Spectrometry. This innovative tool is designed to enhance research in petroleomics, sustainable fuels, and advanced energy storage by providing unparalleled mass resolution for analyzing complex mixtures. The system aims to help scientists develop next-generation lithium-ion batteries with extended lifespan and improved safety, as well as create sustainable, low-carbon transportation fuels from biomass.
BofA Securities Maintains Bruker Corp(BRKR.US) With Buy Rating, Announces Target Price $65
BofA Securities has reiterated its Buy rating for Bruker Corp (BRKR.US) and re-established a target price of $65. This news comes as the firm continues to show confidence in the company's financial prospects and market position.
Wolfe Research Initiates Bruker Corp(BRKR.US) With Hold Rating
Wolfe Research has initiated coverage on Bruker Corp (BRKR.US) with a Hold rating. This indicates a neutral stance on the stock's future performance by the research firm. Investors will likely monitor further reports and company news for more insights into Bruker's trajectory.
Is It Time To Consider Buying Bruker Corporation (NASDAQ:BRKR)?
This article analyzes Bruker Corporation (NASDAQ:BRKR) as a potential investment, focusing on its financial health, growth prospects, and valuation. It delves into aspects like debt management, earnings growth, and share price performance to assess if the current market price reflects a good buying opportunity. The analysis aims to help investors decide if BRKR is an attractive addition to their portfolio.
Bruker Announces Major Strides in 4D Proteomics Performance, Further Advances In Intact and Top-Down Functional Proteoform Analysis, and Innovations in Hybrid Qual/Quant 4D Metabolomics – all to Enable Deeper Insights into Disease Biology
Bruker Corporation announced significant advancements in 4D proteomics, intact and top-down functional proteoform analysis, and hybrid quad/quant 4D metabolomics to enhance disease biology insights. The company launched the timsMRMS system for ultra-high-resolution mass spectrometry and introduced new systems for the energy and semiconductor industries. These innovations aim to deepen the understanding of molecular disease drivers and accelerate drug discovery.
Bruker launches air exposomics tools to link pollution and disease
Bruker has launched new mass spectrometry systems and advancements in proteomics and metabolomics to provide deeper insights into disease biology and the impact of environmental factors. Key launches include the timsMRMS for ultra-high-resolution analysis, advancements in timsUltra AIP for deep proteome coverage, and an "Air Exposomics" initiative combining real-time environmental monitoring with multiomics to link pollution to health outcomes. These innovations aim to accelerate drug discovery, improve precision medicine, and enhance understanding of molecular disease drivers.
Bruker Announces Major Strides in 4D Proteomics Performance, Further Advances In Intact and Top-Down Functional Proteoform Analysis, and Innovations in Hybrid Qual/Quant 4D Metabolomics – all to Enable Deeper Insights into Disease Biology
Bruker Corporation announced significant advancements in 4D proteomics, intact and top-down functional proteoform analysis, and hybrid metabolomics at ASMS 2026. Key innovations include the timsMRMS system for ultra-high-resolution mass spectrometry, enhanced timsUltra AIP performance for deep proteome coverage, and the timsOmni for sensitive proteoform characterization. These developments aim to provide deeper insights into disease biology and accelerate drug discovery.
BRKR - Bruker Corp Stock Price and Quote
This page provides comprehensive financial data for Bruker Corp (BRKR), including its stock price, market capitalization, key financial ratios, and recent performance indicators. It also lists analyst ratings with target prices and a chronological feed of recent news and insider transactions, offering a detailed overview for potential investors.
Bruker (NASDAQ: BRKR) details 2026 vote results and technical 8-K/A update
Bruker Corporation filed an amended 8-K/A report to include omitted Inline XBRL tags for its Series A Preferred Stock, noting that no other disclosures were changed. The report also detailed the results of its 2026 Annual Meeting, where stockholders elected three Class II directors, approved 2025 executive compensation on an advisory basis, and ratified PricewaterhouseCoopers LLP as the independent auditor for fiscal year 2026. The filing provides specific vote counts for each proposal.
Bruker Corp. Hits Day High with 11.87% Surge in Strong Performance
Bruker Corp. has shown significant stock performance, gaining 11.87% to an intraday high of USD 54.40, and outperforming the S&P 500. The company has a one-month gain of 50% and a year-to-date increase of 15.45%. Financially, Bruker reports a 49.12% growth in net profit for the half-year, excellent management efficiency with a 23.72% ROCE, low debt, and an impressive dividend yield of 13.18%.
Bruker (BRKR) Unveils Advanced BioSpec 18T MRI System in Lisbon
Bruker (BRKR) has launched its advanced BioSpec 18 Tesla preclinical MRI system at the Champalimaud Foundation in Lisbon, aiming to boost cancer and neuroscience research with enhanced imaging capabilities. Despite its innovative strides and strong GF Score™ of 83, reflecting profitability and growth, the company faces challenges in financial strength, highlighted by recent insider stock sales. Investors are advised to consider both the technological advancements and financial factors when evaluating BRKR.
Inside the world’s highest-field MRI now probing cancer and the brain in Lisbon
Bruker Corporation announced the commissioning of its new BioSpec™ 18 Tesla preclinical MRI system, the world's highest-field horizontal-bore MRI, at the Champalimaud Foundation in Lisbon, Portugal. This advanced system will support cutting-edge neuroscience and oncology research, enabling in vivo studies of cancer, metastasis, brain plasticity, and neural activity with increased spatial resolution and sensitivity. The technology aims to discover novel imaging biomarkers and advance understanding of biological mechanisms in both healthy and diseased states.
MA-BRUKER-CORP
The article, published by Business Wire on May 26, 2026, announces the delivery of a BioSpec 18 Tesla MRI to Champalimaud. The brief notice suggests a development in the field of health, medical, and diagnostic technology.
Bruker Corporation 8-K SEC Filing Summary – Company Information, Address, and Securities Details (May 21, 2026)
Bruker Corporation (NASDAQ: BRKR) has released the results of its 2026 Annual Meeting of Stockholders held on May 21, 2026. Shareholders approved the election of directors, executive compensation, and the ratification of PricewaterhouseCoopers LLP as the independent auditor. These results indicate stable shareholder support for management and governance, though no extraordinary events were disclosed that would significantly impact the stock price in the short term.
Bruker (NASDAQ: BRKR) investors back board slate and auditor at 2026 meeting
Bruker Corporation (NASDAQ: BRKR) stockholders recently held their 2026 Annual Meeting, electing three Class II directors—Laura A. Francis, John J. (Jack) Phillips, and Hermann F. Requardt, Ph.D.—each for a three-year term. Shareholders also approved, on an advisory basis, the 2025 compensation for named executive officers and ratified PricewaterhouseCoopers LLP as the independent registered public accounting firm for fiscal year 2026. These decisions reflect broad investor support for the company's existing leadership, executive compensation plan, and audit arrangements.
Thrivent Financial for Lutherans Acquires 152,603 Shares of Bruker Corporation $BRKR
Thrivent Financial for Lutherans significantly increased its stake in Bruker Corporation, acquiring an additional 152,603 shares to bring its total to 179,792 shares, valued at approximately $8.47 million. This comes as Bruker reported stronger-than-expected quarterly earnings and raised its FY 2026 guidance. Analysts currently have a "Hold" consensus rating on Bruker, with an average target price of $50.54.
BRUKER CORP - BRKR 6 3/8 09/01/28 (BRKRP) Technical Analysis
This article provides a technical analysis of BRUKER CORP (NASDAQ: BRKRP), assigning it an overall technical rating of 7 out of 10 due to decent short and long-term performance, though it notes underperformance compared to the broader market and its industry peers. The analysis highlights positive short and long-term trends, significant price range fluctuation, key support areas, and signals from various technical indicators including MACD and RSI. However, it cautions against immediate entry due to recently extended prices and low trading volume.
Bruker (BRKR) director receives 2,886 RSUs vesting in 2027
Bruker Corp. director Bernard Thierry was granted 2,886 Restricted Stock Units (RSUs) as part of his compensation, which will vest entirely on May 15, 2027. These RSUs were issued at no cash cost and will convert to Bruker Common Stock shares upon vesting. This transaction is a routine equity award, increasing Thierry's direct holdings to 2,886 shares reflective of this grant.
Bruker (NASDAQ: BRKR) EVP exercises options and sells 2,000 shares under plan
Bruker Corporation's EVP and President of Bruker Nano Inc., Mark Munch, exercised stock options for 2,000 shares at $22.19 and subsequently sold 2,000 shares of common stock at $43.90 on May 15, 2026. These transactions were executed under a pre-arranged Rule 10b5-1 trading plan. After the sale, Munch holds 128,443 shares of common stock and 8,000 stock options.
Bruker Corp stock (US1167941087): upbeat guidance and life-science demand support growth story
Bruker Corp has raised its growth outlook for 2025 and the mid-term due to strong demand for life-science and biopharma tools. The company specializes in high-end scientific instruments like mass spectrometry and NMR, capitalizing on trends in proteomics and precision medicine. While supported by recurring service revenues, its performance can be influenced by academic funding cycles and macroeconomic conditions.
2,000-share proposed sale via option exercise (BRKR) reported
A Form 144 notice reports a proposed insider sale of 2,000 shares of Bruker Corp (BRKR) common stock via a stock option exercise on May 15, 2026, with payment indicated as cash. The filing also details two previous sales of 2,000 shares each on April 15, 2026, and March 13, 2026, by Mark R Munch, generating proceeds of $79,800 and $70,880, respectively. Securities compliance and capital markets analysts view this as a neutral event with limited market impact due to the modest amounts involved.
Orbis group discloses 11.8% stake in Bruker Corp (BRKR)
Orbis Investment Management Ltd, Allan Gray Australia Pty Ltd, and Orbis Investment Management (U.S.), L.P. collectively own 17,940,076 shares of Bruker Corp (BRKR), representing an 11.8% stake. This information was disclosed in an amended Schedule 13G/A filing. Orbis Investment Management Ltd holds the majority of the sole voting and dispositive power for these shares.
Earnings Flash (BRKR) Bruker Corporation Posts Q1 Adjusted EPS $0.31 per Share, Vs. FactSet Est of $0.23
Bruker Corporation (BRKR) reported its Q1 adjusted EPS at $0.31 per share, significantly exceeding the FactSet estimate of $0.23 per share. This financial update highlights a stronger-than-expected performance for the quarter.
Stifel Maintains Bruker Corp(BRKR.US) With Hold Rating, Raises Target Price to $45
Stifel has reiterated its Hold rating on Bruker Corp (BRKR.US) and increased the target price to $45. This adjustment reflects the firm's continued assessment of Bruker's financial performance and market position, leading to a revised valuation.
Bruker Price Target Raised to $45.00/Share From $43.00 by TD Cowen
TD Cowen has increased its price target for Bruker shares to $45.00 from $43.00. This adjustment reflects an updated outlook on the company's valuation.
